Format

Send to

Choose Destination
J Infect Dis. 2012 Jun;205(11):1705-8. doi: 10.1093/infdis/jis269. Epub 2012 Apr 3.

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

Author information

1
Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Erratum in

Abstract

Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.

PMID:
22474037
PMCID:
PMC3415851
DOI:
10.1093/infdis/jis269
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center